

ASRS GLOBAL TRENDS IN RETINA

Africa/Middle East



Asia/Pacific



Central & South America




Europe



ASRS American Society of
Retina Specialists

2020



ASRS

GLOBAL


TRENDS

I N R E T I N A


Survey Highlights

Dean Elliott, MD, Chair, ASRS International Affairs Committee

2020



ASRS International Affairs



**Preferences and Trends
(PAT) Survey**

40 societies accepted our invitation;
722 of their members answered the
2020 Global Trends in Retina Survey

About the Global Trends data

- The Global Trends Survey includes 15 questions from the 2020 ASRS PAT Survey.
- International responses are categorized into 4 regional groups.
- US responses reflect US ASRS members' answers to the same questions in the PAT Survey.
- Because the following graphs reflect some key highlights distilled from the full survey data, the response numbers do not add up to 100%.

GLOBAL TRENDS in Retina

International Affairs Committee Staff Liaison

Caroline Bozell, MS

ASRS PAT Survey Editors

Paul Hahn, MD, PhD, *Editor*

Thomas W. Stone, MD, *Immediate Past Editor*

Susan Raef, MSMC, *Managing Editor*

Research Consultant and Project Manager

Mindy Schneiderman, PhD



GLOBAL TRENDS in Retina

International Affairs Committee

Dean Elliott, MD, Chair

J. Fernando Arevalo, MD, FACS (International Liaison Leader, Americas)


Alay S. Banker, MD (International Liaison Leader, Asia/Pacific)

Ehab N. El-Rayes, MD, PhD (International Liaison Leader, Africa/Middle East)

Marta Figueroa, MD, PhD (International Rep. to the ASRS Board)

Stratos V. Gotzaridis, MBBS, MD (International Rep. to the ASRS Board)

Adnan Tufail, MBBS, MD, FRCOphth (International Liaison Leader, Europe)



Africa/Middle East



Arab African Society of Retina Specialists (AASRS)



Emirates Society of Ophthalmology



Gulf Retina Group



Iranian Vitreoretinal Society



Israel Vitreoretinal Society



The Jordan Vitreoretinal Society




Oman Ophthalmic Society



Saudi Ophthalmological Society



Vitreoretinal Society of Nigeria



Asia/Pacific



Association of Vitreo-Retina Specialists of Sri Lanka



Australian and New Zealand Society of Retinal Specialists



Indonesia Ophthalmology Association, Vitreoretinal Interest Group



Japanese Retina and Vitreous Society



The Korean Retina Society



Malaysian Society of Ophthalmology



Singapore Society of Ophthalmology



Taiwan Retina Society



The Thai Retina Society



Vitreo Retina Society-India

Vitreo Retina Society of India



Vitreo-Retinal Society of the Philippines



Europe



Austrian Ophthalmological Society



British and Eire Association of Vitreoretinal Surgeons (BEAVRS)



Dutch Society of Vitreoretinal Surgery



Dutch Medical Retina Society



European Vitreoretinal Society



French Society of Retina Specialists



Greek Vitreo-Retinal Society (GVRS)



Italian Vitreoretinal Surgery Society



Rosengren Club—Swedish Vitreoretinal Society



Spanish Retina and Vitreous Society (SERV)



Turkish Ophthalmological Society



Ukrainian Alliance of Ophthalmologists



Central & South America



Argentine Retina and Vitreous Society



Brazilian Retina and Vitreous Society



Colombian Retina and Vitreous Association



Mexican Retina Association



Pan-American Retina & Vitreous Society (PRVS)




Peruvian Society of Ophthalmology




Salvadoran Retina and Vitreous Association





Uruguayan Association of Ophthalmology




When do you use commercial genetic testing for assessing age-related macular degeneration (AMD) risk?





Which anti-VEGF agent do you feel delivers the most effective fluid resolution in wet AMD?





How much recurrent extrafoveal SRF would you tolerate in a recently diagnosed wet-AMD patient on a T&E protocol?




How would you treat a 40-year-old symptomatic male with chronic CSR, VA = 20/40, after 6 months?




How would you manage a 30-year-old type 1 diabetic patient with high-risk PDR, VA = 20/20, and no DME?




Which intravitreal agent would you initially choose for *your own* center-involving DME with decreased VA?





For patients requiring chronic anti-VEGF injection therapy, what is your typical approach?




How would you manage a 30-yo asymptomatic pt prior to LASIK with 360° lattice and an atrophic inferior retinal hole?




How will more-durable drugs or drug delivery methods affect your AMD, DME, DR, and RVO patient volume in 5 to 10 years?




At what age do you plan to retire from clinical practice?




Which statement best describes your access to OCT angiography (OCTA)?




When you use traditional silicone oil, what best describes your preference?





How long do you recommend facedown positioning after macular hole repair?




During uncomplicated macular surgery, how often do you perform scleral depression at the end of the case?



What type of IOL would you place in a 35-yo aphakic patient with no capsular support or relevant ocular history?



2020



ASRS

GLOBAL
TRENDS

I N R E T I N A

Thank You